Trusted by research professionals across the UK Manufactured under strict sterile conditions Multi-dose vial designed for ongoing peptide preparation Backed by Bluewells reliable customer support Safety and Compliance Bluewell products are intended strictly for laboratory research purposes only
While retatrutide shows lower potency at human GLP-1 and glucagon receptors compared to natural ligands, it demonstrates higher potency at the GIP receptor by a factor of nearly 9x, and the combined effect is what drives the superior outcomes
It is knowing which patient needs a GLP-1 and which one needs a workup, how to titrate through the nausea window without losing the patient, how to protect lean mass during rapid loss, how to screen for the contraindications that matter, and how to tell a patient honestly what an adjunct will and will not do for them
Pugel, A
Wolverine stack protocol: PDA: 500 mcg to 1 mg subcutaneous, once daily TB-500: 2.0 to 2.5 mg subcutaneous, 2 to 3 times weekly (loading phase), then once weekly (maintenance) Duration: 6 to 8 weeks Timing: PDA and TB-500 can be administered at the same time or at different times during the day
